Lv1
50 积分 2021-08-25 加入
A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial
5天前
已完结
Post-surgery financial toxicity and its influencing factors in colorectal cancer care: A cross-sectional study
1个月前
已完结
Going beyond the 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting
1个月前
已关闭
MASCC antiemetic consensus recommendations: resource-limited settings
1个月前
已完结
ESO-ESMO fifth international consensus guidelines for breast cancer in young women (BCY5)
1个月前
已完结
MASCC antiemetic consensus recommendations: resource-limited settings
1个月前
已完结
Going beyond the 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting
1个月前
已关闭
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
2个月前
已完结
Turning sour into sweet: Lactylation modification as a promising target in cardiovascular health
3个月前
已完结
The role of protein lactylation: A kaleidoscopic post-translational modification in cancer
3个月前
已完结
皖公网安备34019202002308
